Table 1.
Baseline characteristics of enrolled patients
| SITA | SU | TZD | P-value | |
|---|---|---|---|---|
| Patients, n | 83 | 928 | 330 | |
| Age, years (mean [SD]) | 56.2 (9.8) | 66.1 (11.4) | 63.2 (10.1) | <0.001 |
| Male, n (%) | 42 (50.6) | 484 (52.2) | 182 (55.2) | 0.592 |
| Charlson index, n (%) | 0.027 | |||
| 1 | 53 (63.9) | 444 (47.8) | 169 (51.2) | |
| 2–3 | 29 (34.9) | 421 (45.4) | 145 (43.9) | |
| ≥4 | 1 (1.2) | 63 (6.8) | 16 (4.9) | |
| Antihypertensive drugs, n (%) | 51 (61.5) | 682 (73.5) | 233 (70.6) | 0.052 |
| Lipid-lowering drugs, n (%) | 37 (44.6) | 426 (45.9) | 146 (44.2) | 0.862 |
| Respiratory drugs, n (%) | 6 (7.2) | 74 (8.0) | 15 (4.6) | 0.114 |
| Nonsteroidal anti-inflammatory drugs, n (%) | 14 (16.9) | 209 (22.5) | 60 (18.2) | 0.157 |
| Previous hospitalizations, n (%) | 4 (4.8) | 141 (15.2) | 36 (10.9) | 0.009 |
| Number of previous OHD classes, mean (SD) | 1.6 (0.7) | 1.2 (0.4) | 1.3 (0.5) | <0.001 |
| Glycemia, mg/dL (mean [SD]) | 173.5 (58.9) | 164.8 (58.6) | 159.4 (49.9) | 0.115 |
| HbA1c, % (mean [SD]) | 8.3 (1.4) | 8.1 (1.6) | 8.0 (1.4) | 0.300 |
Abbreviations: SITA, sitagliptin; SU, sulphonylureas; TZD, thiazolidinediones; n, number; SD, standard deviation; OHD, oral hypoglycemic drugs; HbA1c, glycated hemoglobin.